Assessing pollination disservices of urban street-trees: The case of London-plane tree (Platanus x hispanica Mill. ex Münchh).

Platanusx hispanica (London plane) is a tree species widely used in urban areas due to the diversity of ecosystem services it provides. However, its functions also have some negative effects or associated disservices, such as the emission of Biogenic Volatile Organic Compounds (BVOCs) and allergens. This work aims to analyze the effect that urban environmental conditions and air pollutants have on pollen emissions of plane tree. The study has been carried out in Granada, in the southeast of the Iberian Peninsula, a city with a Mediterranean climate and one of the most polluted in Spain. Granada is also one of the Mediterranean cities in which the increase in the percentage of the population affected by allergy to Platanus pollen in recent decades has been most significant. The 1992-2019 Platanus pollen data series has been considered to establish the main aerobiological parameters, trends and correlations with meteorological variables and particulate and gaseous atmospheric pollutants, both before and during the flowering period. The average Seasonal Pollen Integral (SPIn) of about 2700 pollen grains has shown a significant increase throughout the series. This increase in allergen emissions could be related to the increase in crown volume associated with tree growth, but also to other environmental factors. Precipitation and minimum temperatures of the winter prior to flowering were the parameters that have shown the most influence with SPIn, while O3 and NOx are the pollutants that have the most effect on the peak value. Due to the good adaptation that London plane has to changing climatic conditions in urban environments, its hegemonic presence as an element of Urban Green infrastructure must be reviewed so that the net balance of ecosystem services is not diminished by the disservices.

Parietaria major allergens vs pollen in the air we breathe.

BACKGROUND: Parietaria and Urtica are the genera from the Urticaceae family more frequent in Mediterranean and Atlantic areas. Moreover, both genera share pollination periods, and their pollen (of the main species) is so similar that there is no aerobiological evidence of the proportion of each of them in the airborne pollen identification, except in the case of U. membranacea. However, Parietaria is one of the most important causes of pollinosis and Urtica is not. Our aim is determine if airborne Urticaceae pollen concentrations show the aerodynamics of the two major allergens of Parietaria (Par j 1 and Par j 2) as well as the allergen distribution in the different-sized particles. METHODS: The air was sampled during the pollination period of Urticaceae using Hirst Volumetric Sampler and Andersen Cascade Impactor in two cities of Southern Spain (Córdoba and Granada). The samples were analysed by the methodology proposed by the Spanish Aerobiology Network (REA) and the minimum requirements of the European Aeroallergen Society (EAS) for pollen, and by ELISA immunoassay for allergens. RESULTS: The patterns of airborne pollen and Par j 1-Par j 2 were present in the air during the studied period, although with irregular oscillations. Urticaceae pollen and Par j 1-Par j 2 allergens located in PM2.5 showed positive and significant correlation during the period with maximum concentrations (March to April). CONCLUSION: Parietaria aeroallergens show similar pattern of Urticaceae airborne pollen. Urticaceae pollen calendar is as a good tool for allergy prevention. On the other hand, important concentrations of Par j 1 and Par j 2 were located in the breathable fraction (PM2.5), which could explain the asthmatic symptoms in the allergic population to Parietaria.

Intraoperative combination of resuscitative endovascular balloon occlusion of the aorta and a median sternotomy in hemodynamically unstable patients with penetrating chest trauma: Is this feasible?

BACKGROUND: Recent evidence suggests that resuscitative endovascular balloon occlusion of the aorta (REBOA) is an effective life-saving intervention in patients with severe torso trauma. However, the deployment of REBOA in patients with isolated penetrating intrathoracic injuries remains controversial. We propose that a median sternotomy be performed in conjunction with REBOA as a feasible and effective means of hemorrhage control in patients suffering from penetrating chest trauma who present hemodynamically unstable. The objective of our study was to present our initial experience with this approach. METHODS: A prospectively collected case series of the use of REBOA (10 Fr) in conjunction with a median sternotomy from January 2015 to December 2016 at a Level I Trauma Center. We included hemodynamically unstable non-compressible torso hemorrhage patients with penetrating chest trauma who underwent intraoperative REBOA deployment plus median sternotomy. RESULTS: A total of 68 trauma-related emergent thoracic surgeries were performed at our institution during the study period. Of these, seven suffered from penetrating chest trauma and non-compressible torso hemorrhage and underwent REBOA plus median sternotomy. Six out of the seven patients suffered intrathoracic vascular injuries: two subclavian arteries, two internal mammary arteries, two aortic arch, and five major central venous injuries. Four patients had an associated lung injury with AIS >3, of which two suffered a pulmonary hilar vessel disruption. REBOA-related complications included one case of upper gastrointestinal bleeding. Six out of the seven patients survived the 30-day follow-up. No adverse neurologic outcomes or deficits were observed in survivors. CONCLUSION: The combined use of REBOA and median sternotomy could be a feasible and effective alternative to hemorrhage control in patients with non-compressible torso hemorrhage secondary to penetrating chest trauma. These findings challenge the recommendation against the use of REBOA in penetrating intrathoracic injuries. Future studies with stronger designs and larger sample sizes are required to confirm our results. LEVEL OF EVIDENCE: Therapeutic, level V.